
    
        <!DOCTYPE html>
        <html lang="hu-HU" data-website-id="1" data-oe-company-name="HBS Medical">
            
<!-- Mirrored from hbs.hu/slides/slide/review-of-intravesical-therapies-for-bladder-pain-syndrome-interstitial-cystitis-2015-41 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 16:19:23 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
                <meta charset="utf-8"/>
                <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"/>
                <meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no"/>

                <title>!!!Review of intravesical therapies for bladder pain syndrome-interstitial cystitis 2015 | HBS</title>
                <link type="image/x-icon" rel="shortcut icon" href="../../web/image/website/1/favicon/index.html"/>

                <script type="text/javascript">
                    var odoo = {
                        csrf_token: "f2e9a41588799d043a772b21ddc3189150ea199fo",
                    };
                </script>

                
            <meta name="generator" content="Odoo"/>

            
            
            
            
            
            
                
                
                
                    
                        <meta property="og:type" content="website"/>
                    
                        <meta property="og:title" content="!!!Review of intravesical therapies for bladder pain syndrome-interstitial cystitis 2015"/>
                    
                        <meta property="og:site_name" content="HBS Medical"/>
                    
                        <meta property="og:url" content="https://hbs.hu/slides/slide/review-of-intravesical-therapies-for-bladder-pain-syndrome-interstitial-cystitis-2015-41"/>
                    
                        <meta property="og:image" content="https://hbs.hu/web/image/slide.slide/41/image_thumb"/>
                    
                        <meta property="og:description"/>
                    
                
                
                
                    
                        <meta name="twitter:card" content="summary_large_image"/>
                    
                        <meta name="twitter:title" content="!!!Review of intravesical therapies for bladder pain syndrome-interstitial cystitis 2015"/>
                    
                        <meta name="twitter:image" content="https://hbs.hu/web/image/slide.slide/41/image_thumb"/>
                    
                        <meta name="twitter:description"/>
                    
                
            

            
            
                
                    <link rel="alternate" hreflang="hu" href="review-of-intravesical-therapies-for-bladder-pain-syndrome-interstitial-cystitis-2015-41.html"/>
                
            

            <script type="text/javascript">
                odoo.session_info = {
                    is_admin: false,
                    is_system: false,
                    is_frontend: true,
                    translationURL: '/website/translations',
                    is_website_user: true,
                    user_id: 4
                };
                
            </script>

            <link type="text/css" rel="stylesheet" href="../../web/content/521-3ab7b2c/1/web.assets_common.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/599-e81acc7/1/web.assets_frontend.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/600-e81acc7/1/web.assets_frontend.1.css"/>
            
            
            

            <script type="text/javascript" src="../../web/content/524-3ab7b2c/1/web.assets_common.js"></script>
            <script type="text/javascript" src="../../web/content/603-e81acc7/1/web.assets_frontend.js"></script>
            
            
            
        
            </head>
            <body>
                
            
        
            
        
        
            
                
                    
                
                
            
        
        
    
    

            
            
        
    
            
          
        <link rel="stylesheet" type="text/css" href="../../sh_cookie_notice/static/src/css/cookieconsent.min.css"/>
        <script type="text/javascript" src="../../sh_cookie_notice/static/src/js/cookieconsent.min.js"></script>
        

	
	<script type="text/javascript"> 

	 window.addEventListener("load", function(){
 
	var sh_msg = String("Az HBS weboldala sütiket használ a weboldal működtetése, használatának megkönnyítése, a weboldalon végzett tevékenység nyomon követése és releváns ajánlatok megjelenítése érdekében.");
	var sh_esc_msg = encodeURIComponent(sh_msg);
	sh_esc_msg = decodeURIComponent(sh_esc_msg); 
	
  	window.cookieconsent.initialise({
	  "palette": {
	    "popup": {
	      "background": "#000" 
	    },
	    "button": {
	      "background": "#f1d600"
	    }
	  },
	  
	  	  "position": "top",
	  
	
	  
	  "content": {
	    "message": sh_esc_msg,
	    "dismiss": "Elfogadom",
	    "allow": "allow",
	    "link": "Adatvédelmi tájékoztató",
	    "href": "/adatkezelesi-tajekoztato"
	  }
	})});
    </script>
 
   
    <div id="wrapwrap" class="   ">
                <header class=" o_affix_enabled">
                    <nav class="navbar navbar-expand-md navbar-light bg-light">
                        <div class="container">
                            <a href="../../index.html" class="navbar-brand logo">
            <span role="img" aria-label="Logo of HBS Medical" title="HBS Medical"><img src="../../web/image/res.company/1/logo66cf.png?unique=866a03a" class="img img-fluid"/></span>
        </a>
    <button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#top_menu_collapse">
                                <span class="navbar-toggler-icon"></span>
                            </button>
                            <div class="collapse navbar-collapse" id="top_menu_collapse">
                                <ul class="nav navbar-nav ml-auto text-right o_menu_loading" id="top_menu">
                                    
        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../index.html" class="nav-link ">
            <span>HBS Medical</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="https://covid-19.hbs.hu" class="nav-link " target="_blank">
            <span>COVID-19</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../blog/hirek-esemenyek-1.html" class="nav-link ">
            <span>Hírek</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../aboutus.html" class="nav-link ">
            <span>Kapcsolat</span>
        </a>
    </li>
    

        
    
                                    
                                </ul>
                            </div>
                        </div>
                    </nav>
                </header>
                <main>
                    
        
        <div class="container mt16">
            <div class="row">
                <div class="col-xl-8 col-lg-8 col-md-12 col-12">
                    

                    <div>
                            
                        <div class="embed-responsive embed-responsive-4by3 embed-responsive-item mb8">
                            <iframe src="../embed/412679.html?page=1" class="o_wslides_iframe_viewer" allowFullScreen="true" height="315" width="420" frameborder="0"></iframe>
                        </div>
                        
                        <div class="row">
                            <h4 class="col-lg-6">!!!Review of intravesical therapies for bladder pain syndrome-interstitial cystitis 2015</h4>
                            <div class="col-lg-6">
                                <div clas="row">
                                    
                                </div>
                            </div>
                        </div>
                        <div class="row">
                            <div class="col-md-8 col-12">
                                <div class="float-left">
                                    <a href="../nyilvanos-anyagok-1.html" title="Channel Nyilvános anyagok" aria-label="Channel Nyilvános anyagok">
                                        <i class="fa fa-circle-o fa-5x" style="color: #875A7B;font-weight: bold;"></i>
                                    </a>
                                </div>
                                <div style="margin-left: 80px">
                                    <p>
                                        <a href="../nyilvanos-anyagok-1.html">Nyilvános anyagok</a>
                                        
                                            <span> / </span>
                                            <a href="../nyilvanos-anyagok-1/category/szakirodalmi-cikkek-3.html">Szakirodalmi cikkek</a>
                                        
                                    </p>
                                    <div>
                                        
        <div class="input-group js_follow" data-id="1" data-object="slide.channel" data-follow="off">
            <input type="email" name="email" class="js_follow_email form-control" placeholder="emailje..."/>
            <div class="input-group-append">
                <button href="#" class="btn btn-secondary js_unfollow_btn">Leiratkozás</button>
                <button href="#" class="btn btn-primary js_follow_btn">Feliratkozás</button>
            </div>
        </div>
    
                                    </div>
                                </div>
                            </div>
                            <div class="col-md-4 d-none d-md-block">
                                <div class="text-right">
                                    <b class="h3 text-muted">987</b> <span class="text-muted small">views</span>
                                </div>
                                
                                <div class="progress mb0" style="height: 2px;">
                                    <div class="progress-bar" role="progressbar" aria-valuenow="0" aria-valuemin="0" aria-valuemax="100" style="width: 0%;">
                                        <span class="sr-only">0 Likes</span>
                                    </div>
                                </div>
                                <div class="text-muted mt4">
                                    <div class="float-right mb16 text-right">
                                        <span class="oe_slide_js_like" data-href="/slides/slide/like" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="41">
                                            <i class="fa fa-thumbs-up fa-1x" role="img" aria-label="Likes" title="Likes"></i>
                                            0
                                        </span>
                                        <span class="oe_slide_js_unlike" data-href="/slides/slide/dislike" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="41">
                                            <i class="fa fa-thumbs-down fa-1x" role="img" aria-label="Dislikes" title="Dislikes"></i>
                                            0
                                        </span>
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="mt8 mb32">
                            <ul class="nav nav-tabs" role="tablist">
                                <li class="nav-item">
                                    <a href="#about" aria-controls="about" role="tab" data-toggle="tab" class="nav-link active">
                                        <i class="fa fa-home"></i> About
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#share" aria-controls="share" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-share-alt"></i> Share
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#discuss" aria-controls="discuss" role="tab" data-toggle="tab" class="nav-link">
                                        <i class="fa fa-comments-o"></i> Comments
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#transcript" aria-controls="transcript" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-align-justify"></i> Transcript
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#statistic" aria-controls="statistic" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-bar-chart"></i> Statistics
                                    </a>
                                </li>
                            </ul>
                            <div class="tab-content" style="padding: 20px 5px 5px 5px; word-wrap: break-word;">
                                <div role="tabpanel" id="about" class="tab-pane fade active in">
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="share">
                                    
    <h4 class="mt0">Share on Social Networks</h4>
    
    <div>
        <a class="o_slides_social_share" social-key="facebook" aria-label="Share on Facebook" title="Share on Facebook" href="https://www.facebook.com/sharer/sharer.php?u=https://hbs.hu/r/Vba"><i class="fa fa-facebook-square fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="twitter" aria-label="Share on Twitter" title="Share on Twitter" href="https://twitter.com/intent/tweet?text=!!!Review%20of%20intravesical%20therapies%20for%20bladder%20pain%20syndrome-interstitial%20cystitis%202015&amp;url=https://hbs.hu/r/Vba"><i class="fa fa-twitter fa-2x"></i></a>
        <a social-key="linkedin" class="o_slides_social_share" aria-label="Share on LinkedIn" title="Share on LinkedIn" href="https://www.linkedin.com/shareArticle?mini=true&amp;url=https://hbs.hu/r/Vba&amp;title=!!!Review%20of%20intravesical%20therapies%20for%20bladder%20pain%20syndrome-interstitial%20cystitis%202015&amp;"><i class="fa fa-linkedin fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="gplus" aria-label="Share on Google Plus" title="Share on Google Plus" href="https://plus.google.com/share?url=https://hbs.hu/r/Vba"><i class="fa fa-google-plus-square fa-2x"></i></a>
    </div>

    <h4 class="mt-3">Share Link</h4>
    <input type="text" class="form-control" readonly="readonly" onClick="this.select();" value="review-of-intravesical-therapies-for-bladder-pain-syndrome-interstitial-cystitis-2015-41.html"/>
    <span class="form-text">Use permanent link to share in social media</span>

                                    
    <h4 class="mt-3">Share with a friend</h4>
    
    
        <p>Please <a href="../../web/login.html?redirect=https://hbs.hu/slides/slide/review-of-intravesical-therapies-for-bladder-pain-syndrome-interstitial-cystitis-2015-41"> login </a> to send this document by email!</p>
    

                                    
                                        
    <div class="oe_slide_js_embed_code_widget">
        <h4 class="mt0">Embed in your website</h4>
        <div class="form-group">
            <textarea class="form-control slide_embed_code" readonly="readonly" onClick="this.select();">&lt;iframe src=&quot;https://hbs.hu/slides/embed/41?page=1&quot; class=&quot;o_wslides_iframe_viewer&quot; allowFullScreen=&quot;true&quot; height=&quot;315&quot; width=&quot;420&quot; frameborder=&quot;0&quot;&gt;&lt;/iframe&gt;</textarea>
        </div>
        <div class="form-group">
            <div class="form-text col-xl-3 col-lg-3 col-md-6 col-6">Select page to start with</div>
            <div class="input-group col-xl-3 col-lg-3 col-md-6 col-6">
                <input type="number" value="1" class="form-control"/>
            </div>
        </div>
    </div>

                                    
                                </div>
                                
                                <div role="tabpanel" id="discuss" class="tab-pane fade">
                                    
        <div id="discussion" class="d-print-none o_portal_chatter o_not_editable p-0" data-res_model="slide.slide" data-res_id="41" data-pager_step="10" data-allow_composer="1">
        </div>
    
                                </div>
                                <div role="tabpanel" class="tab-pane fade oe_slides_transcript" id="transcript">
                                    
                                        
                                            <p>9. 637 Translational Andrology and Urology, Vol 4, No 6 December 2015 Transl Androl Urol  2015;4(6):629-637 www.amepc.org/tau © Translational Andrology and Urology. All rights reserved. patients with urodynamic increased bladder sensation. Eur  Urol 2006;50:1299-305. 55.   Lazzeri M, Spinelli M, Beneforti P, et al. Intravesical  infusion of resiniferatoxin by a temporary in situ drug  delivery system to treat interstitial cystitis: a pilot study.  Eur Urol 2004;45:98-102. 56.   Takahashi S, Yanase M, Inoue R, et al. Intravesical  instillation of resiniferatoxin for the patients with  interstitial cystitis. Hinyokika Kiyo Acta Urologica  Japonica 2006;52:911-3. 57.   Peng CH, Kuo HC. Multiple intravesical instillations of  low-dose resiniferatoxin in the treatment of refractory  interstitial cystitis. Urol Int 2007;78:78-81. 58.   Payne CK, Mosbaugh PG, Forrest JB, et al. Intravesical  resiniferatoxin for the treatment of interstitial cystitis: a  randomized, double-blind, placebo controlled trial. J Urol  2005;173:1590-4. 59.   Chen TY, Corcos J, Camel M, et al. Prospective,  randomized, double-blind study of safety and tolerability  of intravesical resiniferatoxin (RTX) in interstitial  cystitis (IC). Int Urogynecol J Pelvic Floor Dysfunct  2005;16:293-7. 60.   Aghamir SM, Mohseni MG, Arasteh S. Intravesical  Bacillus Calmette-Guerin for treatment of refractory  interstitial cystitis. Urol J 2007;4:18-23. 61.   Mayer R, Propert KJ, Peters KM, et al. A randomized  controlled trial of intravesical bacillus calmette-guerin  for treatment refractory interstitial cystitis. J Urol  2005;173:1186-91. 62.   Propert KJ, Mayer R, Nickel JC, et al. Followup of  patients with interstitial cystitis responsive to treatment  with intravesical bacillus Calmette-Guerin or placebo. J  Urol 2008;179:552-5. 63.   Chuang YC, Lee WC, Lee WC, et al. Intravesical liposome  versus oral pentosan polysulfate for interstitial cystitis/ painful bladder syndrome. J Urol 2009;182:1393-400. Cite this article as:  Cvach K, Rosamilia A. Review of  intravesical therapies for bladder pain syndrome/interstitial  cystitis. Transl Androl Urol 2015;4(6):629-637. doi: 10.3978/ j.issn.2223-4683.2015.10.07 </p>
                                        
                                            <p>7. 635 Translational Andrology and Urology, Vol 4, No 6 December 2015 Transl Androl Urol  2015;4(6):629-637 www.amepc.org/tau © Translational Andrology and Urology. All rights reserved. 5.   Slobodov G, Feloney M, Gran C, et al. Abnormal  expression of molecular markers for bladder impermeability  and differentiation in the urothelium of patients with  interstitial cystitis. J Urol 2004;171:1554-8. 6.   Hanno PM, Erickson D, Moldwin R, et al. Diagnosis and  treatment of interstitial cystitis/bladder pain syndrome:  AUA guideline amendment. J Urol 2015;193:1545-53. 7.   Engeler D, Baranowski AP, Borovicka J, et al. Guidelines  on Chronic Pelvic Pain. European Association of Urology  2015. Available online: http://uroweb.org/wp-content/ uploads/EAU-Guidelines-Chronic-Pelvic-Pain-2015.pdf 8.   Sun Y, Chai TC. Effects of dimethyl sulphoxide and  heparin on stretch-activated ATP release by bladder  urothelial cells from patients with interstitial cystitis. BJU  Int 2002;90:381-5. 9.   Shiga KI, Hirano K, Nishimura J, et al. Dimethyl  sulphoxide relaxes rabbit detrusor muscle by decreasing  the Ca2+ sensitivity of the contractile apparatus. Br J  Pharmacol 2007;151:1014-24. 10.   Ek A, Engberg A, Frodin L, et al. The use of dimethyl- sulfoxide (DMSO) in the treatment of interstitial cystitis.  Scand J Urol Nephrol 1978;12:129-31. 11.   Stewart BH, Shirley SW. Further experience with  intravesical dimethyl sulfoxide in the treatment of  interstitial cystitis. J Urol 1976;116:36-8. 12.   Biggers RD. Self-administration of dimethyl sulfoxide  (DMSO) for interstitial cystitis. Urology 1986;28:10-1. 13.   Fowler JE Jr. Prospective study of intravesical dimethyl  sulfoxide in treatment of suspected early interstitial cystitis.  Urology 1981;18:21-6. 14.   Perez-Marrero R, Emerson LE, Feltis JT. A controlled  study of dimethyl sulfoxide in interstitial cystitis. J Urol  1988;140:36-9. 15.   Peeker R, Haghsheno MA, Holmang S, et al. Intravesical  bacillus Calmette-Guerin and dimethyl sulfoxide for  treatment of classic and nonulcer interstitial cystitis:  a prospective, randomized double-blind study. J Urol  2000;164:1912-5; discussion 1915-6. 16.   Lim Y, Murray CJ, Thomas EA, et al. A long term study  of intravesical dimethyl sulfoxide (DMSO)/heparin/ hydrocortisone/bupivicaine therapy for interstitial  cystitis/bladder pain syndrome (BPS). Int Urogynecol J  2015;26:S127-8. 17.   Lane DA, Adams L. Non-anticoagulant uses of heparin. N  Engl J Med 1993;329:129-30. 18.   Nickel JC, Moldwin R, Lee S, et al. Intravesical alkalinized  lidocaine (PSD597) offers sustained relief from symptoms  of interstitial cystitis and painful bladder syndrome. BJU  Int 2009;103:910-8. 19.   Parsons CL, Housley T, Schmidt JD, et al. Treatment  of interstitial cystitis with intravesical heparin. Br J Urol  1994;73:504-7. 20.   Parsons CL. Successful downregulation of bladder sensory  nerves with combination of heparin and alkalinized  lidocaine in patients with interstitial cystitis. Urology  2005;65:45-8. 21.   Nomiya A, Naruse T, Niimi A, et al. On- and post- treatment symptom relief by repeated instillations of  heparin and alkalized lidocaine in interstitial cystitis. Int J  Urol 2013;20:1118-22. 22.   Chiang G, Patra P, Letourneau R, et al.  Pentosanpolysulfate inhibits mast cell histamine secretion  and intracellular calcium ion levels: an alternative  explanation of its beneficial effect in interstitial cystitis. J  Urol 2000;164:2119-25. 23.   Davis EL, El Khoudary SR, Talbott EO, et al. Safety  and efficacy of the use of intravesical and oral pentosan  polysulfate sodium for interstitial cystitis: a randomized  double-blind clinical trial. J Urol 2008;179:177-85. 24.   Engelhardt PF, Morakis N, Daha LK, et al. Long-term  results of intravesical hyaluronan therapy in bladder  pain syndrome/interstitial cystitis. Int Urogynecol J  2011;22:401-5. 25.   Porru D, Campus G, Tudino D, et al. Results of treatment  of refractory interstitial cystitis with intravesical hyaluronic  acid. Urol Int 1997;59:26-9. 26.   Gupta SK, Pidcock L, Parr NJ. The potassium sensitivity  test: a predictor of treatment response in interstitial  cystitis. BJU Int 2005;96:1063-6. 27.   Kallestrup EB, Jorgensen SS, Nordling J, et al. Treatment  of interstitial cystitis with Cystistat: a hyaluronic acid  product. Scand J Urol Nephrol 2005;39:143-7. 28.   Morales A, Emerson L, Nickel JC. Intravesical hyaluronic  acid in the treatment of refractory interstitial cystitis.  Urology 1997;49:111-3. 29.   Daha LK, Riedl CR, Lazar D, et al. Do cystometric  findings predict the results of intravesical hyaluronic acid  in women with interstitial cystitis? Eur Urol 2005;47:393- 7; discussion 7. 30.   Shao Y, Shen ZJ, Rui WB, et al. Intravesical instillation  of hyaluronic acid prolonged the effect of bladder  hydrodistention in patients with severe interstitial cystitis.  Urology 2010;75:547-50. 31.   Gülpınar O, Haliloglu AH, Gokce MI, et al. Instillation of  Hyaluronic Acid via Electromotive Drug Administration  Can Improve the Efficacy of Treatment in Patients  </p>
                                        
                                            <p>8. 636 Cvach and Rosamilia. Intravesical therapies for the treatment of BPS/IC Transl Androl Urol  2015;4(6):629-637 www.amepc.org/tau © Translational Andrology and Urology. All rights reserved. With Interstitial Cystitis/Painful Bladder Syndrome:  A Randomized Prospective Study. Korean J Urol  2014;55:354-9. 32.   Hanno P. Bladder Pain Syndrome (Interstitial Cystitis)  and Related Disorders. In: Wein AJ, Kavoussi LR, Novick  A, et al, editors. Campbell-Walsh Urology. 10th ed.  Philadelphia, PA: Elsevier Health Sciences, 2012:357-401. 33.   Hurst RE, Roy JB, Min KW, et al. A deficit of chondroitin  sulfate proteoglycans on the bladder uroepithelium in  interstitial cystitis. Urology 1996;48:817-21. 34.   Engles CD, Hauser PJ, Abdullah SN, et al. Intravesical  chondroitin sulfate inhibits recruitment of inflammatory  cells in an acute acid damage “leaky bladder” model of  cystitis. Urology 2012;79:483.e13-7. 35.   Nordling J, van Ophoven A. Intravesical  glycosaminoglycan replenishment with chondroitin  sulphate in chronic forms of cystitis. A multi-national,  multi-centre, prospective observational clinical trial.  Arzneimittel-Forschung 2008;58:328-35. 36.   Nickel JC, Egerdie B, Downey J, et al. A real-life  multicentre clinical practice study to evaluate the efficacy  and safety of intravesical chondroitin sulphate for the  treatment of interstitial cystitis. BJU Int 2009;103:56-60. 37.   Nickel JC, Hanno P, Kumar K, et al. Second multicenter,  randomized, double-blind, parallel-group evaluation of  effectiveness and safety of intravesical sodium chondroitin  sulfate compared with inactive vehicle control in subjects  with interstitial cystitis/bladder pain syndrome. Urology  2012;79:1220-4. 38.   Bassi PF. Insights on clinical use of Ialuril®. 26th Annual  European Association of Urology Congress. 2011 March  18-21. Vienna, Austria. 39.   Cervigni M, Natale F, Nasta L, et al. A combined  intravesical therapy with hyaluronic acid and chondroitin  for refractory painful bladder syndrome/interstitial cystitis.  Int Urogynecol J Pelvic Floor Dysfunct 2008;19:943-7. 40.   Porru D, Leva F, Parmigiani A, et al. Impact of intravesical  hyaluronic acid and chondroitin sulfate on bladder  pain syndrome/interstitial cystitis. Int Urogynecol J  2012;23:1193-9. 41.   Giberti C, Gallo F, Cortese P, et al. Combined intravesical  sodium hyaluronate/chondroitin sulfate therapy for  interstitial cystitis/bladder pain syndrome: a prospective  study. Ther Adv Urol 2013;5:175-9. 42.   Cervigni M, Sommariva M, Porru D, et al. A randomized,  open-label, multicentre study of efficacy and safety of  intravesical hyaluronic acid and chondroitin sulfate (HA  1.6% and CS 2%)  vs.  dimethyl sulfoxide (DMSO 50%)  in women with bladder pain syndrome/interstitial cystitis  (BPS/IC). Neurourol Urodyn 2014;33:665-6. 43.   Kreder K, Lutgendorf S, Knopf MA, et al. Chlorpactin  instillation releases calcitonin gene-related peptide in  interstitial cystitis patients. Urology 2001;57:128-9. 44.   Ikeda Y, Zabbarova IV, Birder LA, et al. Botulinum  neurotoxin serotype A suppresses neurotransmitter release  from afferent as well as efferent nerves in the urinary  bladder. Eur Urol 2012;62:1157-64. 45.   Shie JH, Liu HT, Wang YS, et al. Immunohistochemical  evidence suggests repeated intravesical application of  botulinum toxin A injections may improve treatment  efficacy of interstitial cystitis/bladder pain syndrome. BJU  Int 2013;111:638-46. 46.   Pinto R, Lopes T, Frias B, et al. Trigonal injection of  botulinum toxin A in patients with refractory bladder pain  syndrome/interstitial cystitis. Eur Urol 2010;58:360-5. 47.   Kuo HC. Preliminary results of suburothelial injection of  botulinum a toxin in the treatment of chronic interstitial  cystitis. Urol Int 2005;75:170-4. 48.   Giannantoni A, Cagini R, Del Zingaro M, et al. Botulinum  A toxin intravesical injections for painful bladder  syndrome: impact upon pain, psychological functioning  and Quality of Life. Curr Drug Deliv 2010;7:442-6. 49.   Giannantoni A, Porena M, Costantini E, et al.  Botulinum A toxin intravesical injection in patients with  painful bladder syndrome: 1-year followup. J Urol  2008;179:1031-4. 50.   Kuo HC, Jiang YH, Tsai YC, et al. Intravesical botulinum  toxin-A injections reduce bladder pain of interstitial  cystitis/bladder pain syndrome refractory to conventional  treatment - A prospective, multicenter, randomized,  double-blind, placebo-controlled clinical trial. Neurourol  Urodyn 2015. [Epub ahead of print]. 51.   Lee CL, Kuo HC. Intravesical botulinum toxin a injections  do not benefit patients with ulcer type interstitial cystitis.  Pain Physician 2013;16:109-16. 52.   Manning J, Dwyer P, Rosamilia A, et al. A multicentre,  prospective, randomised, double-blind study to measure  the treatment effectiveness of abobotulinum A (AboBTXA)  among women with refractory interstitial cystitis/bladder  pain syndrome. Int Urogynecol J 2014;25:593-9. 53.   Fagerli J, Fraser MO, deGroat WC, et al. Intravesical  capsaicin for the treatment of interstitial cystitis: a pilot  study. Can J Urol 1999;6:737-44. 54.   Apostolidis A, Gonzales GE, Fowler CJ. Effect of  intravesical Resiniferatoxin (RTX) on lower urinary tract  symptoms, urodynamic parameters, and quality of life of  </p>
                                        
                                            <p>1. Transl Androl Urol  2015;4(6):629-637 www.amepc.org/tau © Translational Andrology and Urology. All rights reserved. Introduction Bladder pain syndrome/interstitial cystitis (BPS/IC) is a  chronic pain syndrome characterised by pain/discomfort  attributed to the bladder, with associated urgency and  urinary frequency. According to the American Urological  Association (AUA) guidelines, symptoms should be present  for a period of more than 6 weeks (1). Confusable diseases,  such as overactive bladder and recurrent urinary tract  infection, need to be excluded prior to a diagnosis of BPS/IC. The underlying etiology of BPS/IC is not well  understood and it is likely that a number of mechanisms  play a role in the development of the condition. The  urothelium/transitional epithelium is thought to play a  fundamental role in the pathogenesis of BPS/IC. The  protective layer of glycosaminoglycans (GAG) on the  surface of the urothelial cells provides a barrier against  solutes in the urine. Components of this layer include  hyaluronic acid (HA), chondroitin sulfate (CS), heparin  sulfate, dermatan sulfate and keratin sulfate (2). This GAG  layer has been shown to be defective in some patients with  BPS/IC (3-5). Once the subepithelial cells come into contact with  urinary solutes, an inflammatory reaction is triggered,  in turn resulting in decreased urothelial production of  GAG and exacerbation of urothelial permeability and  inflammation. Urothelial damage results in pathologic  C-fiber activation, causing smooth muscle contraction,  neurogenic inflammation, and hypersensitivity. As with  other chronic pain conditions, central pain sensitisation  results.  Management of BPS/IC requires a multimodal approach.  The AUA and the European Urological Association have  produced management guidelines for BPS/IC, both of  which were updated in 2014 (6,7).  First line therapy is aimed at educating the patient  about the chronic nature of the condition and advocating  behavioural and lifestyle modifications that may help  ameliorate the symptoms, as well as providing a pain  management plan.  Intravesical therapies are indicated if first line therapy  fails and are used in conjunction with physiotherapy  techniques (myofascial release/pelvic floor muscle  relaxation) and oral agents. The rationale for the use of  Review Article Review of intravesical therapies for bladder pain syndrome/ interstitial cystitis Kristina Cvach 1 , Anna Rosamilia 2 1 Mercy Hospital for Women, Melbourne, Australia;  2 Monash Medical Centre, Melbourne, Australia Contributions:  (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: Non e;    (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing:  All authors; (VII) Final  approval of manuscript: All authors. Correspondence to:  Kristina Cvach, MD. Mercy Hospital for Women, 163 Studley Road, Heidelberg 3084, Australia. Email: <a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="9cf7ffeafdfff4dcfbf1fdf5f0b2fff3f1b2">[email&#160;protected]</a> Abstract:  Bladder pain syndrome/interstitial cystitis (BPS/IC) is a chronic pain condition characterised by  urinary frequency, urgency and pain or discomfort which the patient attributes to the bladder. It is a complex  condition to manage and treat and requires a multi-disciplinary and multi-modal approach. As well as  lifestyle and behavioural modifications, physical therapy and oral medications, intravesical treatments can be  used in the treatment algorithm for BPS/IC. A number of intravesical agents are reviewed in this paper along  with the available evidence for their use. Keywords:  Bladder pain syndrome (BPS); interstitial cystitis (IC); intravesical therapy; instillation therapy Submitted Aug 24, 2015. Accepted for publication Sep 01, 2015. doi: 10.3978/j.issn.2223-4683.2015.10.07 View this article at:  http://dx.doi.org/10.3978/j.issn.2223-4683.2015.10.07 </p>
                                        
                                            <p>6. 634 Cvach and Rosamilia. Intravesical therapies for the treatment of BPS/IC Transl Androl Urol  2015;4(6):629-637 www.amepc.org/tau © Translational Andrology and Urology. All rights reserved. BPS/IC patients (51). Manning  et al.  reported on the use of abobotulinumtoxin  A (Dysport ® , Ipsen Biopharmaceuticals Inc., Basking Ridge,  NJ, USA) (52). This was a multi-centre, randomised,  double-blind placebo-controlled trial in 54 patients. Dysport  500 U suburothelial injections plus hydrodistension was  compared to normal saline injections plus hydrodistention.  O’Leary Sant overall scores were improved in both groups  at 3 months with no statistically significant difference seen  between the two groups. Only the OLS-problem index  improved in the Dysport group (P=0.04). Interestingly, this  study found that post-treatment UTI was a confounder and  that when the 12 patients were excluded from the analysis,  the OLS overall score and OLS-symptom index were  significantly improved in the Dysport group. The authors  concluded that Dysport may be beneficial in a small number  of patients and that patients without post-treatment UTI  had a better response. Other intravesical therapies Capsaicin and resiniferatoxin are C-fiber afferent  neurotoxins. They have been considered as candidates  for treatment of BPS/IC based on their theoretical ability  to alleviate bladder symptoms by desensitising bladder  afferents (53). Whilst clinical efficacy for resiniferatoxin was  initially demonstrated in a number of small studies (54-57),  these results have not been confirmed in placebo-controlled  studies (58,59). They are currently not recommended for  intravesical use in BPS/IC patients. Bacillus Calmette-Guerin (BCG) is an immunomodulatory  agent used for the intravesical treatment of bladder cancer.  An initial open label study provided promising results (60),  however a randomised double blind study demonstrated  no clinical benefit (61,62). Adverse events may be serious  and therefore BCG is not recommended for use in BPS/IC  patients. Liposomes are phospholipid vesicles and when applied  to cell walls they create a molecular film. It is believed that  they may be able to restore the GAG layer. A small pilot  study has shown significant improvement in frequency,  nocturia, and pain in 24 patients undergoing intravesical  liposomal instillations compared to oral PPS (63). A  randomised, placebo-controlled trial is currently underway  assessing the efficacy of two doses of intravesical liposomal  therapy compared to placebo (https://clinicaltrials.gov/ show/NCT01393223. Access date July 30, 2015). Authors’ recommendations/comments BPS/IC is a challenging condition to manage and is likely  made up of a number of clinical phenotypes which respond  differently to the various treatments. It is a condition that  requires a multi-disciplinary and multi-modal approach.  Having a number of intravesical and oral agents available to  each individual patient is important. The availability of instillation agents depends on  geographical location. Off-label use is common as a result  of non-approval of agents by local drug approval agencies.  Based on available evidence, DMSO, GAGs and Botulinum  toxin appear to be safe with efficacy in the range of 60-80%    however these figures are largely based on open-label,  uncontrolled trials. Medium to long-term effects are  variable. Some studies have pointed out that BPS/IC patients with  ulcer disease or a low capacity bladder have a less successful  response to bladder instillations such as DMSO and Botox  (16,49). Ongoing research to provide high quality data  including subgroup analysis is needed. These trials need  to be well-planned and executed, using comparator groups  (either “placebo” or other agents) and using validated  outcome tools to measure response to treatment. Acknowledgements None. Footnote Conflicts of Interest:  The authors have no conflicts of interest  to declare. References 1.   Interstitial Cystitis/Bladder Pain Syndrome. 2014. Accessed  30th July, 2015. Available online: http://www.auanet.org/ education/guidelines/ic-bladder-pain-syndrome.cfm 2.   Hurst RE. Structure, function, and pathology of  proteoglycans and glycosaminoglycans in the urinary tract.  World J Urol 1994;12:3-10. 3.   Rajasekaran M, Stein P, Parsons CL. Toxic factors  in human urine that injure urothelium. Int J Urol  2006;13:409-14. 4.   Parsons CL, Forrest J, Nickel JC, et al. Effect of pentosan  polysulfate therapy on intravesical potassium sensitivity.  Urology 2002;59:329-33. </p>
                                        
                                            <p>2. 630 Cvach and Rosamilia. Intravesical therapies for the treatment of BPS/IC Transl Androl Urol  2015;4(6):629-637 www.amepc.org/tau © Translational Andrology and Urology. All rights reserved. many of the currently used intravesical therapies is to  replenish the deficient GAG layer or to alter the process of  neurogenic inflammation and hypersensitivity. Intravesical therapy has the advantages of localising  therapy to the bladder, with the establishment of high  concentrations of the agent and minimising systemic side  effects. The disadvantages are that delivery of the agent  requires instrumentation of the urethra and bladder with  the potential for exacerbating pain and increasing the risk of  urinary tract infection. This review of intravesical therapies for the treatment  of BPS/IC summarises the rationale and evidence for the  use of these agents. A PubMed search was performed using  the terms “bladder pain syndrome”, “interstitial cystitis”,  “intravesical”, “instillation” along with the names of the  individual agents, with publication dates up to June 2015.  Reference lists of reviewed articles were also searched for  additional papers. Intravesical therapies Dimethyl sulfoxide (DMSO) Mechanism of action DMSO is an organosulfur non-toxic solvent used in  the treatment of BPS/IC since the 1970’s when it was  approved by the US Food and Drug Administration (FDA)  for intravesical use. It is likely to exert its clinical effect  through several mechanisms: reducing inflammation,  acting as an analgesic and facilitating detrusor relaxation  (8,9). It can be given as a single-agent instillation at a 50%  concentration or, more commonly, as part of a ‘cocktail’  with methylprednisolone or hydrocortisone, alkalised  lidocaine and heparin sulfate. Instillation regimens differ  but a common treatment program involves twice weekly  instillations for 4 weeks and then weekly instillations for a  further 4 weeks, for a total of 12 instillations. Repeat full,  partial (four weekly instillations) or maintenance (monthly)  treatment courses for persistent or recurrent symptoms are  possible. Evidence Both the AUA and EAU guidelines list DMSO as one of  the instillation agents of choice. This is largely based on a  few small case series published in the 1970’s and 80’s with  variable follow-up and using non-standardised outcome  measures. Response rates in these studies range from    70-95% (10-13). Perez-Marrero  et al.  performed a randomised, placebo- controlled crossover trial in 33 patients and assessment was  based on urodynamics and symptoms (14). Compared to  placebo, DMSO showed higher objective (35%  vs.  93%)  and subjective (18%  vs.  53%) improvement. Peeker  et al.   performed a randomised, double-blind crossover study  comparing DMSO to intravesical BCG in 21 patients (15).  Each group underwent six weekly instillations and crossed- over to the other treatment if no improvement was noted.  Patients were assessed with symptom questionnaires, VAS  pain scale and voiding diaries. No improvement in any of  the outcome measures were seen following BCG (but the  study was likely to be underpowered). DMSO resulted in  significant reductions in pain and urinary frequency. Ghoniem  et al.  utilised a DMSO cocktail (premixed    50 mL solution of 50% DMSO, 40 mg methylprednisolone  and 5,000 units of heparin sulfate) in a case series of    25 patients. Six instillations (the first performed under  general anaethesia after hydrodistention) were administered  at weekly intervals. Outcome measures were not well  defined, with 92% achieving initial remission for an average  of 8 months. Nine patients (36%) had one or more relapses  and required further instillations or oral therapy. Lim  et al.  reported long-term outcomes following  DMSO cocktail instillation (50 mL of 50% DMSO,    100 mg hydrocortisone, 0.25% bupivicaine and 5,000 units  heparin) (16). Mean follow-up of 55 patients was at 4.65 years  and overall improvement as assessed on ICSI/ICPI and  VAS pain scores was 23-47%. At long-term follow-up 34%  were cured after one course, a further 22% required oral  medication, 24% had a DMSO top-up; the remainder went  on to receive other treatments. Anaesthetic bladder capacity  ≤ 500 mL was associated with a lower response rate. Heparin and lidocaine Mechanism of action Heparin is a sulfonated GAG with the theoretical action of  replenishing the urothelial GAG layer. Heparin also acts  as an anti-inflammatory, inhibits fibroblast proliferation  and promotes angiogenesis and smooth muscle cell    proliferation (17). Lidocaine is a topical anaesthetic and  is used as a single-agent instillation or, more commonly,  in combination with heparin. It is given in a variety of  formulations and concentrations and usually in combination  with an alkalising agent (sodium bicarbonate) to avoid  ionisation within urine and to better penetrate the  urothelium (18).  </p>
                                        
                                            <p>4. 632 Cvach and Rosamilia. Intravesical therapies for the treatment of BPS/IC Transl Androl Urol  2015;4(6):629-637 www.amepc.org/tau © Translational Andrology and Urology. All rights reserved. this cohort who were contacted at a mean follow-up of    5 years (24). Fifty percent (24/48) had sustained improvement  and did not require any further treatment. Forty-one  percent continued with intermittent HA instillation therapy  with or without oral pentosan polysulfate. A number of smaller case series have reported  improvement rates with HA instillation of between 30-85%  with varying follow-up times and instruments used to assess  outcomes (25-29). Shao  et al.  performed a prospective open-label  controlled trial in 47 patients examining the use of HA  after hydrodistention (30). Patients with functional bladder  capacities &lt;200 mL underwent hydrodistension followed  by treatment with either HA (n=20) or a heparin/lidocaine  cocktail (n=16). Treatments occurred weekly for 4 weeks,  then monthly for a further 2 months. Eleven patients served  as ‘controls’ undergoing only hydrodistention. Assessment  was based on urinary frequency, bladder capacity, and VAS  pain score at baseline and 3, 6 and 9 months following  hydrodistension. At 6 months, 78% in the HA group  and 33% in the heparin group had improvement in their  symptoms versus 9% in the hydrodistension group. At    9 months, improvement was sustained (but diminished) in  the HA group but not in the heparin group. There were  no adverse effects related to HA or heparin however two  patients had bladder rupture during hydrodistension. Gulpinar  et al.  reported on the use of electromotive  drug administration (EMDA) to improve the efficacy  of HA treatment (31). EMDA increases tissue uptake of  drug compared with passive diffusion. Thirty-one patients  were randomised to instillation of HA alone (n=15) or  HA with EMDA with placement of suprapubic electrodes  (n=16). Patients were not blinded to treatment allocation.  Follow-up was at 1, 6, 12 and 24 months. Both groups  had statistically significant improvement in all parameters  assessed (urinary frequency, nocturia, VAS pain, voided  volume, ICSI/ICPI and global response assessment) at    6 and 12 months; the percentage of responders was higher  in the EMDA group than in the HA alone group (69%  vs.  58%, P=0.042). By 24 months, only voiding frequency  and VAS pain scores were still significantly improved from  baseline in both groups. Two industry-sponsored (Bioniche Life Sciences and  Seikagaku Corporation) randomised, placebo-controlled  trials of HA were completed in 2003/2004 (32). Both trials  showed non-significant improvements in the treatment  group compared to placebo and remain unpublished in the  peer-reviewed literature. Chondroitin sulfate (CS) Mechanism of action CS is a component of the GAG layer and has been shown  to be deficient in patients with BPS/IC (33). As well as its  role in the GAG layer, CS has been shown to inhibit the  recruitment of inflammatory cells to the deep layers of the  bladder wall (34). Evidence Nordling  et al.  conducted a multi-centre, prospective  observational trial of 40 mL of 0.2% CS (Gepan ®  Instill,  Pohl-Boskamp GmbH, Hohenlockstedt, Germany) in  286 patients with chronic cystitis (51% were BPS/IC  patients) (35). Instillations occurred weekly for the first 4-   6 weeks, then monthly until 12 weeks with a maximum of  8 instillations. Outcome measures from baseline to end of  study included change in daytime and nocturnal frequency,  urgency and pain scores and a global response assessment.  Overall, statistically significant changes were seen in all  parameters and this was also seen in a subgroup analysis of  the BPS/IC patients. GRA response was 76%. Nickel  et al.  conducted a similar multi-centre, prospective  observational study of 20 mL 2% CS (Uracyst ® , Stellar  Pharmaceuticals Inc., London, ON, Canada) (36). Fifty- three patients underwent 6 weekly instillations followed  by a further four instillations at monthly intervals. Global  response was assessed at week 10 and 24 with rates of 47%  and 60%, respectively. At week 24, ICSI and ICPI scores  significantly decreased as did VAS pain and urgency scores. More recently, Nickel  et al.  conducted a randomised,  double-blind, inactive vehicle control trial of 20 mL 2%  CS (Uracyst ® , Stellar Pharmaceuticals Inc., London, ON,  Canada) (37). Ninety-eight patients underwent eight weekly  instillations, then monthly treatments to a maximum of  10. No statistically significant results were obtained with  respect to GRA (treatment group 38%  vs.  control 31%) or  based on changes in ICSI/ICPI scores, frequency, urgency,  voided volume or VAS pain scores. The authors noted that  the study was underpowered and based on these results  would require a total of 1,500 patients to be adequately  powered to show a difference in outcomes between the two  groups, however the author’s conclusion was that single- agent therapy with CS could not be supported. Sodium hyaluronate and chondroitin sulfate (HA-CS) Mechanism of action HA-CS has been shown to reduce the production of  </p>
                                        
                                            <p>3. 631 Translational Andrology and Urology, Vol 4, No 6 December 2015 Transl Androl Urol  2015;4(6):629-637 www.amepc.org/tau © Translational Andrology and Urology. All rights reserved. Evidence Single-agent heparin studies have shown modest benefit in  patients with BPS/IC. Parsons  et al.  reported on 48 patients  undergoing instillation with 10,000 units of heparin 3 times    a week for 3 months. Fifty-six percent attained “good  clinical remission” (19). Single-agent alkalised lidocaine (200 mg lidocaine plus  8.4% sodium bicarbonate, 10 mL) was reported by Nickel  et al.  in a randomised, double-blind placebo-controlled  industry sponsored study of 102 patients (18). Instillations  occurred daily for 5 consecutive days. The primary outcome  was based on a Global Response Assessment. On day 8,  patients in the lidocaine group had significantly higher  improvement than placebo (30%  vs.  10%, P=0.012); this  improvement was still present at day 15 but not statistically  significant (24%  vs.  12%, P=0.102). Eighty-two patients  elected to continue on to the open-label phase of the study  and underwent a further 5-day course of lidocaine with  similar rates of improvement. In an effort to improve response rates, multi-agent  therapy with heparin and alkalised lidocaine has been  studied. Parsons  et al.  have studied the efficacy of heparin  and alkalised lidocaine in a total of 82 patients (20). Group  1 received 40,000 units heparin, 8 mL of 1% lidocaine  and 3 mL of 8.4% sodium bicarbonate. Group 2 received  an increased concentration of lidocaine (8 mL of 2%  lidocaine). Immediate relief of pain and frequency after    1 instillation was higher in group 2 than group 1 (94%  vs.   75%; P&lt;0.01). Twenty patients in group 2 underwent a  further 6 instillations over 2 weeks, 80% showed symptom  relief persisting at least 48 hours after the last treatment.  Improved duration of effect was shown by Nomiya  et al.  in  a study of 32 patients undergoing 12 weekly instillations of  20,000 units heparin, 5 mL 4% lidocaine and 25 mL 7%  sodium bicarbonate. On GRA, 76% responded at the end  of treatment, with responses of 90% at 1 month, 46% at    2 months and 16% at 6 months following treatment (21). Pentosan polysulfate sodium (PPS) Mechanism of action PPS is the only oral agent approved for BPS/IC by the  FDA. It is an oral heparinoid and likely exerts its effect in  the treatment of BPS/IC by restoring the GAG layer. It  also inhibits histamine release by mast cells and reduces  the intracellular calcium ion levels in the bladder (22). The  main disadvantage is the low urine concentrations achieved,  resulting in a lag time of up to 6 months before clinical  improvement is observed. Intravesical therapy has the  theoretical advantage of achieving a more rapid response to  PPS treatment.  Evidence Davis  et al.  performed a randomised, double-blind  controlled study comparing oral PPS and intravesical PPS  to oral PPS and intravesical placebo in 41 patients (23).  Instillations occurred twice weekly for 6 weeks whilst  oral therapy was given for a total of 18 weeks. At the end  of the study period, the treatment group were shown to  have a statistically greater reduction in ICSI/ICPI scores  compared to placebo (46% reduction  vs.  24% reduction;  P=0.04). Health-related quality of life domains also showed  statistically greater improvement in the treatment group.  Sodium hyaluronate (HA) Mechanism of action The rationale for using HA is to replenish deficiencies in  the GAG layer although other biological activities including  enhancement of connective tissue healing and inhibition  of leukocyte migration and aggregation may contribute to  its action in BPS/IC patients. HA is commercially available  as Cystistat (Teva UK Limited); it comes as a 40 mg dose  in a 50 mL solution. Most studies use a treatment regimen  consisting of four weekly instillations followed by monthly  therapy until symptoms have resolved. Evidence Riedl  et al.  prospectively studied the efficacy of HA in    126 patients as first line therapy. Weekly instillations of HA  were given until patients were significantly improved or  symptom free. Assessment was based on a non-standardised  questionnaire using a VAS symptom score, impact on  quality of life question and willingness to undergo repeat  instillation therapy. This was administered at baseline  and at a mean of 6 months after the last HA instillation.  The average number of instillations was 12.2. Eighty- five percent of patients reported symptom improvement    ( ≥ 2 VAS units); 55% had no or minimal bladder symptoms  after therapy. Eighty-four percent reported improved  quality of life (although this was not objectively quantified)  and 86% would undergo repeat HA treatment if necessary.  Thirty-four percent had recurrence of symptoms and  required further instillations—the duration of effect before  restarting treatment was not stated. The same group then  published long-term follow-up data of 48/70 patients from  </p>
                                        
                                            <p>5. 633 Translational Andrology and Urology, Vol 4, No 6 December 2015 Transl Androl Urol  2015;4(6):629-637 www.amepc.org/tau © Translational Andrology and Urology. All rights reserved. proinflammatory cytokines, reduce urothelial permeability,  and facilitate the repair of the protective GAG layer (38).  HA-CS is available as a 50 mL proprietary preparation  (Ialuril ® ; IBSA Institut Biochimique SA, Lugano,  Switzerland) containing 1.6% HA and 2% CS with calcium  chloride in water. Evidence To date, three small case series with a total of 63 patients  have been published assessing treatment response to    HA-CS (39-41). Instillations occurred weekly for a period of  4-20 weeks, with further biweekly or monthly instillations  until treatment response was assessed. All studies  reported significant changes from baseline in ICSI/ICPI    scores. Cervigni and Porru showed significant changes from  baseline in VAS pain and urgency scores.  Cervigni  et al.  presented at ICS 2014 an IBSA funded  study comparing 13 weekly instillations of Ialuril with  DMSO in a 2:1 random allocation with 110 subjects with  ESSIC criteria for BPS (42). The baseline demographics  and VAS pain scores were similar. The results were a VAS  score reduction of −39 (SD 25)  vs.  −31 (SD 26) points for  ialuril and DMSO respectively. Response at 6 months  defined as &gt;30% reduction of the VAS from baseline was  73%  vs.  58% for ialuril and DMSO respectively. Adverse  events were higher in the DMSO group at 31%  vs.  15%.  There were seven dropouts overall and were evenly divided.  Oxychlorosene sodium (OS) Mechanism of action OS is a stabilised organic derivative of hypochlorous acid.  It has been used as an antibacterial agent extensively in  general surgery, particularly in the irrigation of wounds. It  is available as a proprietary preparation under the name of  Clorpactin ®  (Guardian Laboratiories, United-Gueardian  Inc, Hauppauge, New York, USA). Its use in the BPS/IC  population stemmed from its role in tuberculous cystitis,  when infection was thought to be an inciting event in the  BPS/IC cascade. The exact mechanism of action of OS in  BPS/IC is unclear but some have hypothesised that it may  act by desensitising or degranulating bladder nociceptive  nerve endings (43). Evidence Initial case series published in the 1950’s and 1970’s  provided some encouraging results, with response rates of  70-80%. OS has been designated as a historical treatment  in a number of reviews of intravesical therapy for BPS/ IC. The authors are currently involved in a multi-centre,  randomised, single-blind controlled trial assessing the  efficacy of a single instillation of 0.4% OS under general  anaesthesia compared to hydrodistension (Australian New  Zealand Clinical Trials Registry: 12611000717954). Botulinum toxin A Mechanism of action Botulnum toxin A is a potent neurotoxin. It has been  shown to inhibit the release of acetylcholine and other  neurotransmitters from both afferent and efferent nerve  terminals as well as ATP from the urothelium (44).  Chronic inflammation and apoptotic signalling molecules  is significantly reduced following intravesical botulinum  toxin A injections, but only after repeated injections (45).  The recently amended AUA guidelines for the treatment of  BPS/IC have moved botulinum toxin A from 5th to first 4th  line treatment (1). Evidence Most studies of botulinum toxin A use onabotulinum  toxin A (Botox ® , Allergan, Irvine, CA, USA). A number of  case series with between 11-16 patients each, showed that  intravesical injections of 100-200 units of Botox resulted  in high response rates of 71-100% (46-49). Significant  reductions in VAS pain scores, urinary daytime and night- time frequency were seen at 3 months follow-up. These  studies varied in the dose injected, the number of injections  and the site of injection (trigonal  vs.  supratrigonal). Kuo  et al.  performed a multi-centre, randomised,  double-blind placebo-controlled trial of Botox in BPS/IC  patients refractory to conventional treatment (50). Forty  patients underwent suburothelial injections of 100 units    Botox and hydrodistension whilst 20 control patients  underwent normal saline injections and hydrodistension.  At 8 weeks post-treatment, overall success was greater in  the Botox group compared to the control group (63%  vs.   15%, P=0.028). VAS pain scores (−2.6  vs.  −0.9, P=0.021)  and cystometric capacity (+67.8  vs.  −45.4, P=0.02) were  also significantly changed in the Botox group compared to  placebo. Adverse events including dysuria (16/40 Botox,  1/20 control), urinary tract infection (2 Botox), urinary  retention (1 Botox) and haematuria (1 Botox) were all  greater in the Botox group. In a prospective case series of  44 patients undergoing 6 monthly Botox injections, Lee and  Kuo reported that Botox was not beneficial in ulcer type  </p>
                                        
                                            <p></p>
                                        
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="statistic" slide-url="review-of-intravesical-therapies-for-bladder-pain-syndrome-interstitial-cystitis-2015-41.html">
                                    <div class="row">
                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Nézetek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">987</span>
                                                    <i class="fa fa-play"></i> Total Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">730</span>
                                                    <i class="fa fa-circle-o"></i> Website Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">257</span>
                                                    <i class="fa fa-code"></i> Embedded Views
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Műveletek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="total-share">0</span>
                                                    <i class="fa fa-share-alt"></i> Social Shares
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-up"></i> Likes
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-down"></i> Nemkedvelések
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-comments-o"></i> Comments
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Share count</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="facebook-badge">0</span>
                                                    <i class="fa fa-facebook-square"></i> Facebook
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="twitter-badge">0</span>
                                                    <i class="fa fa-twitter-square"></i> Twitter
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="linkedin-badge">0</span>
                                                    <i class="fa fa-linkedin-square"></i> LinkedIn
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="google-badge">0</span>
                                                    <i class="fa fa-google-plus-square"></i> Google+
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                    <div class="row">
                                        <div class="col-lg-12">
                                            <h4 class="mt0"> Embeds
                                                <span class="badge badge-pill float-right">
                                                    3
                                                </span>
                                            </h4>
                                            <ul class="list-group" style="height: 150px;overflow: auto;">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">1</span>
                                                    hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">2</span>
                                                    www.hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">2</span>
                                                    odoo.hbs.hu
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="col-xl-4 col-lg-4 col-md-12 col-12">
                    <ul class="nav nav-tabs" role="tablist">
                        <li class="nav-item"><a aria-controls="related" href="#related" class="nav-link active" data-toggle="tab">Kapcsolódó</a></li>
                        <li class="nav-item"><a aria-controls="most_viewed" href="#most_viewed" class="nav-link" data-toggle="tab">Most Viewed</a></li>
                    </ul>
                    <div class="tab-content">
                        <div role="tabpanel" id="related" class="tab-pane active mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1558 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1504 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/19/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html"><h6 class="mb-1">Cikk a Neurourology and Urodynamics-ban 2018.</h6></a>
            <small class="text-muted">
                1473 Views . <timeago class="timeago" datetime="2019-10-31 13:28:23.618732"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1498 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-diagnostic-algorhytm-21.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/21/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-diagnostic-algorhytm-21.html"><h6 class="mb-1">IC-BPS diagnostic algorhytm.</h6></a>
            <small class="text-muted">
                1488 Views . <timeago class="timeago" datetime="2019-10-31 13:29:57.450898"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="glycosaminoglycan-therapy-for-bladder-diseases-22.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/22/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="glycosaminoglycan-therapy-for-bladder-diseases-22.html"><h6 class="mb-1">Glycosaminoglycan Therapy for Bladder Diseases</h6></a>
            <small class="text-muted">
                1385 Views . <timeago class="timeago" datetime="2019-10-31 13:30:10.980936"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="essic-2017-budapest-abstracts-23.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/23/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="essic-2017-budapest-abstracts-23.html"><h6 class="mb-1">ESSIC 2017 Budapest abstracts</h6></a>
            <small class="text-muted">
                1464 Views . <timeago class="timeago" datetime="2019-10-31 13:30:38.129948"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/24/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html"><h6 class="mb-1">Prevalence of Symptoms of Bladder Pain Syndrome 2011</h6></a>
            <small class="text-muted">
                1304 Views . <timeago class="timeago" datetime="2019-10-31 13:30:57.131521"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/25/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html"><h6 class="mb-1">The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment. 2017</h6></a>
            <small class="text-muted">
                1362 Views . <timeago class="timeago" datetime="2019-10-31 13:35:55.689470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/26/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html"><h6 class="mb-1">Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis. 2016</h6></a>
            <small class="text-muted">
                1299 Views . <timeago class="timeago" datetime="2019-10-31 13:36:14.959707"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/27/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html"><h6 class="mb-1">PENTOSAN POLYSULFATE SODIUM FOR THERAPY of IC Urology 1990</h6></a>
            <small class="text-muted">
                1414 Views . <timeago class="timeago" datetime="2019-10-31 13:37:27.415502"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/28/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html"><h6 class="mb-1">Interstitial cystitis intravesical therapy tau-06-S2-S171 2017</h6></a>
            <small class="text-muted">
                1368 Views . <timeago class="timeago" datetime="2019-10-31 13:38:04.204366"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/29/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html"><h6 class="mb-1">Novel targeted bladder drug-delivery systems rru-7-169 2015</h6></a>
            <small class="text-muted">
                1489 Views . <timeago class="timeago" datetime="2019-10-31 13:38:18.425299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/30/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html"><h6 class="mb-1">Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections 2016 bmjopen-2015-009669</h6></a>
            <small class="text-muted">
                1221 Views . <timeago class="timeago" datetime="2019-10-31 13:38:52.835202"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/31/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html"><h6 class="mb-1">Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections- Results from a multicentre survey.cuaj-9-10-e721</h6></a>
            <small class="text-muted">
                1388 Views . <timeago class="timeago" datetime="2019-10-31 13:39:08.628954"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/32/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html"><h6 class="mb-1">IC_BPS and glycosaminoglycans replacement therapy 2015 tau-04-06-638</h6></a>
            <small class="text-muted">
                1251 Views . <timeago class="timeago" datetime="2019-10-31 13:39:22.993300"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/33/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html"><h6 class="mb-1">Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans- an update on the evidence 2016 Urology</h6></a>
            <small class="text-muted">
                1389 Views . <timeago class="timeago" datetime="2019-10-31 13:40:52.836690"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/34/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html"><h6 class="mb-1">Hyaluronic Acid and Its Composites as a Local Antimicrobial-Antiadhesive Barrier 2017.jbjiv02p0063</h6></a>
            <small class="text-muted">
                1311 Views . <timeago class="timeago" datetime="2019-10-31 13:45:41.648470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/35/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html"><h6 class="mb-1">Evidence-based criteria for the pain of IC_BPS in women 2008 nihms43157</h6></a>
            <small class="text-muted">
                1301 Views . <timeago class="timeago" datetime="2019-10-31 13:45:59.326213"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/36/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html"><h6 class="mb-1">Intravesical Glycosaminoglycan Replacement with Chondroitin_2015_Article_306</h6></a>
            <small class="text-muted">
                1359 Views . <timeago class="timeago" datetime="2019-10-31 13:46:19.773972"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                        <div role="tabpanel" id="most_viewed" class="tab-pane  mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="sugarvedo-ruhazat-ismerteto-3.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/3/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="sugarvedo-ruhazat-ismerteto-3.html"><h6 class="mb-1">Sugárvédő ruházat ismertető</h6></a>
            <small class="text-muted">
                3284 Views . <timeago class="timeago" datetime="2018-10-20 14:31:25.547995"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="op-set-system-5.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/5/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="op-set-system-5.html"><h6 class="mb-1">OP Set System</h6></a>
            <small class="text-muted">
                3044 Views . <timeago class="timeago" datetime="2018-11-16 13:38:03.543744"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kompresszios-polya-felhelyezese-8.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/8/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kompresszios-polya-felhelyezese-8.html"><h6 class="mb-1">Kompressziós pólya felhelyezése</h6></a>
            <small class="text-muted">
                2846 Views . <timeago class="timeago" datetime="2018-11-16 13:39:25.884480"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kotszer-polya-l-r-6.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/6/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kotszer-polya-l-r-6.html"><h6 class="mb-1">Kötszer Pólya L&amp;R</h6></a>
            <small class="text-muted">
                2643 Views . <timeago class="timeago" datetime="2018-11-16 13:38:35.611223"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="nedves-sebkezeles-flyer-l-r-7.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/7/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="nedves-sebkezeles-flyer-l-r-7.html"><h6 class="mb-1">Nedves sebkezelés flyer L&amp;R</h6></a>
            <small class="text-muted">
                2438 Views . <timeago class="timeago" datetime="2018-11-16 13:38:59.835920"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-liner-10.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/10/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-liner-10.html"><h6 class="mb-1">PDB_Actico UlcerSys Liner</h6></a>
            <small class="text-muted">
                2324 Views . <timeago class="timeago" datetime="2018-11-16 13:39:54.728282"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-2.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/2/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-2.html"><h6 class="mb-1">SciCan STATIM G4</h6></a>
            <small class="text-muted">
                2321 Views . <timeago class="timeago" datetime="2018-10-20 14:10:02.671163"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-9.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/9/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-9.html"><h6 class="mb-1">PDB_Actico UlcerSys</h6></a>
            <small class="text-muted">
                2209 Views . <timeago class="timeago" datetime="2018-11-16 13:39:42.488113"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-hasznalati-utmutato-v1-1-12.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/12/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-hasznalati-utmutato-v1-1-12.html"><h6 class="mb-1">UroStill_hasznalati_utmutato_v1.1</h6></a>
            <small class="text-muted">
                2038 Views . <timeago class="timeago" datetime="2019-10-31 13:22:24.531510"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="koronavirus-jarvany-61.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/61/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="koronavirus-jarvany-61.html"><h6 class="mb-1">KORONAVIRUS JARVANY</h6></a>
            <small class="text-muted">
                1774 Views . <timeago class="timeago" datetime="2020-04-09 15:16:22.317496"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-1.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/1/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-1.html"><h6 class="mb-1">SciCan Statim G4</h6></a>
            <small class="text-muted">
                1709 Views . <timeago class="timeago" datetime="2018-10-20 14:09:31.661802"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="new-aiding-device-for-self-instillation-v2-16.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/16/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="new-aiding-device-for-self-instillation-v2-16.html"><h6 class="mb-1">New_aiding_device_for_self-instillation_v2</h6></a>
            <small class="text-muted">
                1690 Views . <timeago class="timeago" datetime="2019-10-31 13:23:48.863175"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kitpack-11.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/11/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="kitpack-11.html"><h6 class="mb-1">Kitpack</h6></a>
            <small class="text-muted">
                1684 Views . <timeago class="timeago" datetime="2018-11-16 14:52:39.736537"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="icbps-szoszedet-14.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/14/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="icbps-szoszedet-14.html"><h6 class="mb-1">ICBPS_SZÓSZEDET</h6></a>
            <small class="text-muted">
                1620 Views . <timeago class="timeago" datetime="2019-10-31 13:23:06.826135"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/15/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html"><h6 class="mb-1">IC - FAQ-s and appropriate answers Mumbai 2019</h6></a>
            <small class="text-muted">
                1612 Views . <timeago class="timeago" datetime="2019-10-31 13:23:19.219912"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-users-manual-v1-1-13.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/13/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-users-manual-v1-1-13.html"><h6 class="mb-1">UroStill_Users_Manual_v1.1</h6></a>
            <small class="text-muted">
                1605 Views . <timeago class="timeago" datetime="2019-10-31 13:22:47.677753"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="l-r-corporate-film-4.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/4/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="l-r-corporate-film-4.html"><h6 class="mb-1">L&amp;R Corporate Film</h6></a>
            <small class="text-muted">
                1601 Views . <timeago class="timeago" datetime="2018-11-14 15:53:51.760680"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1558 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1504 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1498 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    
                </main>
                <footer class="bg-light o_footer">
                    <div id="footer" class="oe_structure oe_structure_solo">
      <section class="s_text_block pb8 pt40">
        <div class="container">
          <div class="row" style="border-top: solid 1px #ddd; padding-top: 30px;">
            <div class="col-lg-4">
              <h5>További tartalmak</h5>
              <ul class="list-unstyled">
                <li>
                  <a href="../../blog/hirek-esemenyek-1.html" data-original-title="" title="" aria-describedby="tooltip310735">Hírek</a>
                  <br/>
                  <a href="../../adatkezelesi-tajekoztato.html">Adatkezelési tájékoztató</a>
                </li>
                <li>
                  <br/>
                </li>
              </ul>
            </div>
            <div class="col-lg-4" id="connect">
              <h5>Elérhetőségek</h5>
              <ul class="list-unstyled">
                <li>
                  <i class="fa fa-phone"></i>
                  <span data-note-id="2">+36 1 452 1700</span>
                </li>
                <li>
                  <i class="fa fa-envelope"></i>
                  <span><a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="5d34333b321d353f2e733528">[email&#160;protected]</a></span>
                </li>
              </ul>
              <p> </p>
            </div>
            <div class="col-lg-4">
              <h5>
                <span>HBS Medical</span>
                <small> – <a href="../../aboutus.html" data-original-title="" title="" aria-describedby="tooltip425138">Kapcsolat</a></small>
              </h5>
              <p>&nbsp;<br/></p>
            </div>
          </div>
        </div>
      </section>
    </div>
  <div class="o_footer_copyright">
            <div class="container">
                <div class="row">
                    <div class="col-lg-6 text-muted text-center text-md-left">
                        <span>Copyright &copy;</span> <span itemprop="name">HBS Medical</span>
                        
    

                    </div>
                    <div class="col-lg-6 text-right o_not_editable">
                        
    <!--<div class="o_brand_promotion text-muted">
        Az oldalt készítette:
        <a href="https://eyssen.hu/" target="_blank"><img src="../../web/image/606/eyssen_logo_blue.png" width="120"/></a>
    </div>-->

                    </div>
                </div>
            </div>
        </div>
    </footer>
            </div>
        <script data-cfasync="false" src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script id="tracking_code">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

            ga('create', _.str.trim('UA-52898474-1'), 'auto');
            ga('send','pageview');
        </script>
    
        
            </body>
        
<!-- Mirrored from hbs.hu/slides/slide/review-of-intravesical-therapies-for-bladder-pain-syndrome-interstitial-cystitis-2015-41 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 16:19:27 GMT -->
</html>
    
    
